🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Been working on a mini-comic about cancer cachexia. Cancer cachexia can be one of the most emotionally-charged symptoms we work with in clinic, for patients AND families. #palliativecare #supponc #hapc #wip #graphicmedicine

In this editorial, Susan F. Slovin, MD, PhD, reviews the recent trial by Daniel E Spratt et al. and discusses the prospects and limitations of applying an AI-based predictive model to guide treatment for prostate cancer. #MedicalAI #PCSM #UroSoMe Memorial Sloan Kettering Cancer Center Sidney Kimmel Comprehensive Cancer Center

We are hiring a Genitourinary Medical Oncologist to provide outstanding patient-centered care at our Monmouth Regional site in NJ. We are looking for either a clinical investigator or a clinician for this role. Join a great team! See ad for details. careers.mskcc.org/vacancies/2023…

Happy ASCO #ASCOGI24 submission day to those who celebrate (late-breaking abstracters: this tweet does not apply to you)

⭐️Unprecedented amount of PRACTICE CHANGING studies in GU oncology ESMO - Eur. Oncology this weekend. Looking forward to seeing these presentations from Bradley McGregor Toni Choueiri, MD Neeraj Agarwal, MD, FASCO Tom Powles Andrea Apolo, M.D. Oliver Sartor silke gillessen OncoAlert Dates and times 👇

Next-Generation Aniten Masofaniten Gains Momentum in mCRPC Andy Laccetti MD, MS Memorial Sloan Kettering Cancer Center #pcsm onclive.com/view/next-gene…

Phase 1/2 Trial: Oral EPI-7386 + Enza vs Enza Alone in mCRPC: Ph 1 Results #ESMO23 UroToday.com Andy Laccetti MD, MS 📍To date, n=18 📍Safety: consistent w/ 2nd-gen antiandrogens 📍PK results: Enza minimally impacted by EPI-7386 --> full dose Enza (160 mg) in cohort 4 📍Evaluable data:

Andrew Laccetti, MD, MS, at Memorial Sloan Kettering Cancer Center underscores “to date, androgen receptor (AR) pathway inhibitors either competitively antagonize the receptor via the ligand-binding domain or block androgen synthesis.” ow.ly/s8NB50PZOWg Andy Laccetti MD, MS #ESMO23

ADT interruption in patients responding exceptionally to AR-pathway inhibitor in #mHSPC: A-DREAM. Atish Choudhury, MD PhD and Alicia Morgans, MD, MPH Dana-Farber discuss the right balance of treatment duration for patients with metastatic prostate cancer > bit.ly/3NOBSOK

We are pleased to announce the PCCTC-managed study of EPI-7386 in combination with enzalutamide in subjects with metastatic prostate cancer has entered phase 2. For more information visit: classic.clinicaltrials.gov/ct2/show/NCT05…

Masofaniten Plus Enzalutamide Demonstrates Safety and Durable Responses in mCRPC Andy Laccetti MD, MS Memorial Sloan Kettering Cancer Center ESMO - Eur. Oncology #ESMO23 #pcsm onclive.com/view/masofanit…

‼️ This combination IIT for pts w refractory penile cancer supported by GSK US is accruing pts Moffitt Cancer Center Philippe spiess and soon at MD Anderson Cancer Center Curtis Pettaway, MD and USC Norris Comprehensive Cancer Center please offer this option to your pts and reach out w questions Global Society of Rare GU Tumors

Dual action hormone therapy targeting two parts of the androgen receptor simultaneously shows tolerability and early efficacy in phase I trial. Andy Laccetti MD, MS Memorial Sloan Kettering Cancer Center and Rana McKay, MD, FASCO UC San Diego discuss recent advancements in #mCRPC treatments > bit.ly/47JrY9N

The efficacy and resistance-breaking potential of EPI-7386 masofaniten in castration-resistant #ProstateCancer. Andy Laccetti MD, MS Memorial Sloan Kettering Cancer Center joins Zach Klaassen Georgia Cancer Center discussing the continuous effort to refine hormonal therapy in #PCa management > bit.ly/3OM2CAD

app.medall.org/event-listings…

Synapse: Your Connection to our MSK Authors Meet: Ritesh Kotecha Ritesh Kotecha Research Focus: Medicine; Assistant Attending Sample site impacts RNA biomarkers for renal cell carcinoma #RenalCellCarcinoma #CancerBiomarkers #RNAResearch synapse.mskcc.org/synapse/works/…

Everyone in academic medicine is hopeful the pause at NIH will be temporary. The research funding pause will affect post doctoral researchers, technicians, and academic research efforts across the United States. msnbc.com/opinion/msnbc-…

DARO monotherapy in CSPC after BCR: ARAMON lead-in phase results UroToday.com Bayer Oncology Medical #GU25 ☑️n=23 ☑️At wk 12: mean % ⬆️ in T from B/L was 53.5% (95%CI, 33.4–76.5) ☑️PSA responses: - <0.2: 65.2% - PSA50: 100% - PSA90: 78.3% ☑️Feminizing TEAEs - 18/23 pts: - Gr 1

This was the date set in the end of year (2024) appropriations bill passed by the prior Congress and signed by President Biden. This new Congress was always going to have to provide for a statutory extension. We knew this in December. I’m confident Congress will act. Our

ADT remodels the tumor microenvironment from immunologically cold to hot. Matthew Dallos, MD Memorial Sloan Kettering Cancer Center joins Andrea Miyahira Prostate Cancer Foundation in this discussion of how androgen deprivation therapy reshapes the immune landscape in localized #ProstateCancer. #WatchNow >